{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:46:09Z","timestamp":1792683969784,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucormycosis is a rare but life-threatening invasive fungal infection that primarily affects immunocompromised patients. Data on its presentation, management, and prognosis in the intensive care unit setting remain scarce. We aimed to evaluate 90-day mortality and to explore clinical, microbiological, therapeutic, and immunological factors associated with outcome in critically ill patients with mucormycosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective multicenter cohort study included patients diagnosed with mucormycosis and admitted to the ICUs of the\n                      <jats:italic>Hospices Civils de Lyon<\/jats:italic>\n                      between January 2014 and July 2023. Patients were identified through mycological records and hospital discharge codes. Univariable analysis and multivariable Cox model were performed to identify factors associated with 90-day mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 43 patients included, hematological malignancy and trauma were the most common underlying conditions (26% each), followed by solid organ transplantation (21%), and burns (16%). Cutaneous forms (49%) predominated, especially among trauma and burn patients, while pulmonary and rhinocerebral forms were mostly observed in previously immunocompromised individuals. The number of mucormycosis diagnoses increased nearly threefold over the study period, paralleling the implementation of\n                      <jats:italic>Mucorales<\/jats:italic>\n                      -specific polymerase chain reaction. Antifungal therapy was initiated in 39 patients (91%); first-line treatment was liposomal amphotericin B in 32 (74%), at a median maximum dose of 7.5 [3.5\u20139.4] mg\/kg\/day, and 12 (28%) received a combination therapy. The 90-day mortality was 47%. In the multivariable Cox model, older age, hematological malignancy, and a higher Sequential Organ Failure Assessment score at diagnosis were independently associated with mortality, while lower liposomal amphotericin B dosing was associated with mortality in univariable analysis. In eight patients without previous immunosuppression and uncontrolled disease, immune monitoring was performed and revealed decreased monocyte HLA-DR expression at 4556 [4194\u20136936] Ab\/c, in favor of injury-induced immunosuppression. Among them, six patients received interferon-gamma as immunotherapy; four responded immunologically and survived.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mucormycosis in critically ill patients is associated with high mortality, particularly in those with hematological malignancies. Polymerase chain reaction\u2013based diagnostics may allow earlier detection, and immune monitoring could help identify high-risk patients, particularly in trauma and burn settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-026-06227-y","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:23:40Z","timestamp":1785493420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mucormycosis in critically ill patients: a 9-year multicenter cohort study of clinical features, management, and 90-day outcomes"],"prefix":"10.1186","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-4067","authenticated-orcid":false,"given":"Frank","family":"Bidar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Maamcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Tirard-Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Friggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Fellahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Jacquet-Lagr\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Aubrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Argaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Dailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Venet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Valour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Persat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rimmel\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"6227_CR1","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405\u201321. https:\/\/doi.org\/10.1016\/S1473-3099(19)30312-3.","journal-title":"Lancet Infect Dis"},{"key":"6227_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.burns.2022.05.012","volume":"49","author":"J Dang","year":"2023","unstructured":"Dang J, Goel P, Choi KJ, Massenzio E, Landau MJ, Pham CH, et al. Mucormycosis following burn injuries: A systematic review. Burns. 2023;49:15\u201325. https:\/\/doi.org\/10.1016\/j.burns.2022.05.012.","journal-title":"Burns"},{"key":"6227_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof5030057","volume":"5","author":"TJ Walsh","year":"2019","unstructured":"Walsh TJ, Hospenthal DR, Petraitis V, Kontoyiannis DP. Necrotizing Mucormycosis of Wounds Following Combat Injuries, Natural Disasters, Burns, and Other Trauma. J Fungi (Basel). 2019;5:57. https:\/\/doi.org\/10.3390\/jof5030057.","journal-title":"J Fungi (Basel)"},{"key":"6227_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/432579","volume":"41","author":"MM Roden","year":"2005","unstructured":"Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634\u201353. https:\/\/doi.org\/10.1086\/432579.","journal-title":"Clin Infect Dis"},{"key":"6227_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/590004","volume":"47","author":"G Chamilos","year":"2008","unstructured":"Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503\u20139. https:\/\/doi.org\/10.1086\/590004.","journal-title":"Clin Infect Dis"},{"key":"6227_CR6","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3201\/eid1509.090334","volume":"15","author":"D Bitar","year":"2009","unstructured":"Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997\u20132006. Emerg Infect Dis. 2009;15:1395\u2013401. https:\/\/doi.org\/10.3201\/eid1509.090334.","journal-title":"Emerg Infect Dis"},{"key":"6227_CR7","doi-asserted-by":"publisher","first-page":"810e1","DOI":"10.1016\/j.cmi.2015.12.006","volume":"22","author":"L Millon","year":"2016","unstructured":"Millon L, Herbrecht R, Grenouillet F, Morio F, Alanio A, Letscher-Bru V, et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin Microbiol Infect. 2016;22:810e1. https:\/\/doi.org\/10.1016\/j.cmi.2015.12.006.","journal-title":"Clin Microbiol Infect"},{"key":"6227_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1080\/10428194.2016.1204652","volume":"58","author":"C Mariette","year":"2017","unstructured":"Mariette C, Tavernier E, Hocquet D, Huynh A, Isnard F, Legrand F, et al. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. Leuk Lymphoma. 2017;58:586\u201393. https:\/\/doi.org\/10.1080\/10428194.2016.1204652.","journal-title":"Leuk Lymphoma"},{"key":"6227_CR9","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/cid\/cis195","volume":"54","author":"F Lanternier","year":"2012","unstructured":"Lanternier F, Sun H-Y, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis. 2012;54:1629\u201336. https:\/\/doi.org\/10.1093\/cid\/cis195.","journal-title":"Clin Infect Dis"},{"key":"6227_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13613-020-00673-9","volume":"10","author":"J Claustre","year":"2020","unstructured":"Claustre J, Larcher R, Jouve T, Truche A-S, Nseir S, Cadiet J, et al. Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy. Ann Intensive Care. 2020;10:74. https:\/\/doi.org\/10.1186\/s13613-020-00673-9.","journal-title":"Ann Intensive Care"},{"key":"6227_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13613-021-00818-4","volume":"11","author":"M Jestin","year":"2021","unstructured":"Jestin M, Azoulay E, P\u00e8ne F, Bruneel F, Mayaux J, Murgier M, et al. Poor outcome associated with mucormycosis in critically ill hematological patients: results of a multicenter study. Ann Intensive Care. 2021;11:31. https:\/\/doi.org\/10.1186\/s13613-021-00818-4.","journal-title":"Ann Intensive Care"},{"key":"6227_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S1473-3099(13)70001-X","volume":"13","author":"RS Hotchkiss","year":"2013","unstructured":"Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13:260\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(13)70001-X.","journal-title":"Lancet Infect Dis"},{"key":"6227_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/CCM.0000000000005270","volume":"50","author":"F Venet","year":"2022","unstructured":"Venet F, Textoris J, Blein S, Rol M-L, Bodinier M, Canard B, et al. Immune Profiling Demonstrates a Common Immune Signature of Delayed Acquired Immunodeficiency in Patients With Various Etiologies of Severe Injury. Crit Care Med. 2022;50:565\u201375. https:\/\/doi.org\/10.1097\/CCM.0000000000005270.","journal-title":"Crit Care Med"},{"key":"6227_CR14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367\u201376. https:\/\/doi.org\/10.1093\/cid\/ciz1008.","journal-title":"Clin Infect Dis"},{"key":"6227_CR15","doi-asserted-by":"publisher","first-page":"101010","DOI":"10.1016\/j.lanepe.2024.101010","volume":"45","author":"L Gouzien","year":"2024","unstructured":"Gouzien L, Che D, Cassaing S, Lortholary O, Letscher-Bru V, Paccoud O, et al. Epidemiology and prognostic factors of mucormycosis in France (2012\u20132022): a cross-sectional study nested in a prospective surveillance programme. Lancet Reg Health - Europe. 2024;45:101010. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101010.","journal-title":"Lancet Reg Health - Europe"},{"key":"6227_CR16","doi-asserted-by":"publisher","unstructured":"Kellum J, Lameire N, Aspelin P, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Supplements. 2012;1\u2013138. https:\/\/doi.org\/10.1038\/kisup.2012.1.","DOI":"10.1038\/kisup.2012.1"},{"key":"6227_CR17","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1093\/cid\/cit094","volume":"56","author":"L Millon","year":"2013","unstructured":"Millon L, Larosa F, Lepiller Q, Legrand F, Rocchi S, Daguindau E, et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin Infect Dis. 2013;56:e95\u2013101. https:\/\/doi.org\/10.1093\/cid\/cit094.","journal-title":"Clin Infect Dis"},{"key":"6227_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/cyto.b.21043","volume":"84B","author":"J Demaret","year":"2013","unstructured":"Demaret J, Walencik A, Jacob M-C, Timsit J-F, Venet F, Lepape A, et al. Inter-laboratory assessment of flow cytometric monocyte HLA-DR expression in clinical samples. Cytometry. 2013;84B:59\u201362. https:\/\/doi.org\/10.1002\/cyto.b.21043.","journal-title":"Cytometry"},{"key":"6227_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13613-022-01010-y","volume":"12","author":"C de Roquetaillade","year":"2022","unstructured":"de Roquetaillade C, Dupuis C, Faivre V, Lukaszewicz AC, Brumpt C, Payen D. Monitoring of circulating monocyte HLA-DR expression in a large cohort of intensive care patients: relation with secondary infections. Ann Intensive Care. 2022;12:39. https:\/\/doi.org\/10.1186\/s13613-022-01010-y.","journal-title":"Ann Intensive Care"},{"key":"6227_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1186\/s12879-019-4526-x","volume":"19","author":"D Payen","year":"2019","unstructured":"Payen D, Faivre V, Miatello J, Leentjens J, Brumpt C, Tissi\u00e8res P, et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infect Dis. 2019;19:931. https:\/\/doi.org\/10.1186\/s12879-019-4526-x.","journal-title":"BMC Infect Dis"},{"key":"6227_CR21","doi-asserted-by":"publisher","first-page":"103115","DOI":"10.1016\/j.eclinm.2025.103115","volume":"81","author":"L Brown","year":"2025","unstructured":"Brown L, Tschiderer L, Alanio A, Barnes RA, Chen SC-A, Cogliati M, et al. The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis. eClinicalMedicine Elsevier BV. 2025;81:103115. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103115.","journal-title":"eClinicalMedicine Elsevier BV"},{"key":"6227_CR22","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","volume":"17","author":"A Skiada","year":"2011","unstructured":"Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859\u201367. https:\/\/doi.org\/10.1111\/j.1469-0691.2010.03456.x.","journal-title":"Clin Microbiol Infect"},{"key":"6227_CR23","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1093\/cid\/cir880","volume":"54","author":"F Lanternier","year":"2012","unstructured":"Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005\u20132007). Clin Infect Dis. 2012;54:S35\u201343. https:\/\/doi.org\/10.1093\/cid\/cir880.","journal-title":"Clin Infect Dis"},{"key":"6227_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/cid\/ciab1066","volume":"75","author":"L Millon","year":"2022","unstructured":"Millon L, Caillot D, Berceanu A, Bretagne S, Lanternier F, Morio F, et al. Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial. Clin Infect Dis. 2022;75:777\u201385. https:\/\/doi.org\/10.1093\/cid\/ciab1066.","journal-title":"Clin Infect Dis"},{"key":"6227_CR25","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/cid\/ciw563","volume":"63","author":"M Legrand","year":"2016","unstructured":"Legrand M, Gits-Muselli M, Boutin L, Garcia-Hermoso D, Maurel V, Soussi S, et al. Detection of Circulating Mucorales DNA in Critically Ill Burn Patients: Preliminary Report of a Screening Strategy for Early Diagnosis and Treatment. Clin Infect Dis. 2016;63:1312\u20137. https:\/\/doi.org\/10.1093\/cid\/ciw563.","journal-title":"Clin Infect Dis"},{"key":"6227_CR26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1128\/AAC.01488-07","volume":"52","author":"AS Ibrahim","year":"2008","unstructured":"Ibrahim AS, Gebremariam T, Husseiny MI, Stevens DA, Fu Y, Edwards JE, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother. 2008;52:1573\u20136. https:\/\/doi.org\/10.1128\/AAC.01488-07.","journal-title":"Antimicrob Agents Chemother"},{"key":"6227_CR27","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/jac\/dkv236","volume":"70","author":"F Lanternier","year":"2015","unstructured":"Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, et al. Prospective pilot study of high-dose (10\u00a0mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015;70:3116\u201323. https:\/\/doi.org\/10.1093\/jac\/dkv236.","journal-title":"J Antimicrob Chemother"},{"key":"6227_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","volume":"62","author":"D Morales Castro","year":"2023","unstructured":"Morales Castro D, Dresser L, Granton J, Fan E. Pharmacokinetic Alterations Associated with Critical Illness. Clin Pharmacokinet. 2023;62:209\u201320. https:\/\/doi.org\/10.1007\/s40262-023-01213-x.","journal-title":"Clin Pharmacokinet"},{"key":"6227_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrneph.2017.165","volume":"14","author":"F Venet","year":"2018","unstructured":"Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018;14:121\u201337. https:\/\/doi.org\/10.1038\/nrneph.2017.165.","journal-title":"Nat Rev Nephrol"},{"key":"6227_CR30","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00134-006-0204-8","volume":"32","author":"G Monneret","year":"2006","unstructured":"Monneret G, Lepape A, Voirin N, Boh\u00e9 J, Venet F, Debard A-L, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 2006;32:1175\u201383. https:\/\/doi.org\/10.1007\/s00134-006-0204-8.","journal-title":"Intensive Care Med"},{"key":"6227_CR31","doi-asserted-by":"publisher","first-page":"795052","DOI":"10.3389\/fimmu.2021.795052","volume":"12","author":"M Bodinier","year":"2021","unstructured":"Bodinier M, Peronnet E, Brengel-Pesce K, Conti F, Rimmel\u00e9 T, Textoris J, et al. Monocyte Trajectories Endotypes Are Associated With Worsening in Septic Patients. Front Immunol. 2021;12:795052. https:\/\/doi.org\/10.3389\/fimmu.2021.795052.","journal-title":"Front Immunol"},{"key":"6227_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/SHK.0000000000000347","volume":"43","author":"K-P Chung","year":"2015","unstructured":"Chung K-P, Chang H-T, Lo S-C, Chang L-Y, Lin S-Y, Cheng A, et al. Severe lymphopenia is associated with elevated plasma interleukin-15 levels and increased mortality during severe sepsis. Shock. 2015;43:569\u201375. https:\/\/doi.org\/10.1097\/SHK.0000000000000347.","journal-title":"Shock"},{"key":"6227_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1471-2334-14-166","volume":"14","author":"CE Delsing","year":"2014","unstructured":"Delsing CE, Gresnigt MS, Leentjens J, Preijers F, Frager FA, Kox M, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis. 2014;14:166. https:\/\/doi.org\/10.1186\/1471-2334-14-166.","journal-title":"BMC Infect Dis"},{"key":"6227_CR34","doi-asserted-by":"publisher","unstructured":"Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, Efthymiou A, Koutsoukou V, Ehler J et al. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. JAMA [Internet]. 2025 [cited 2026 Feb 12]; https:\/\/doi.org\/10.1001\/jama.2025.24175","DOI":"10.1001\/jama.2025.24175"},{"key":"6227_CR35","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00134-023-07065-0","volume":"49","author":"A Roquilly","year":"2023","unstructured":"Roquilly A, Francois B, Huet O, Launey Y, Lasocki S, Weiss E, et al. Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial. Intensive Care Med. 2023;49:530\u201344. https:\/\/doi.org\/10.1007\/s00134-023-07065-0.","journal-title":"Intensive Care Med"},{"key":"6227_CR36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-025-09882-3","volume":"649","author":"A Pikoulas","year":"2026","unstructured":"Pikoulas A, Morianos I, Nidris V, Hamdy R, Intze E, L\u00f3pez-L\u00f3pez \u00c1, et al. Albumin orchestrates a natural host defence mechanism against mucormycosis. Nature. 2026;649:693\u2013702. https:\/\/doi.org\/10.1038\/s41586-025-09882-3.","journal-title":"Nature"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-026-06227-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:25:11Z","timestamp":1792682711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-026-06227-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6227"],"URL":"https:\/\/doi.org\/10.1186\/s13054-026-06227-y","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of the Hospices Civils de Lyon (Comit\u00e9 Scientifique et Ethique des HCL, CSE-HCL \u2013 IRB 00013204; reference 23-5475). The research was conducted in accordance with the Declaration of Helsinki. All participants or their relatives were informed and did not object to the use of their data, in accordance with French regulations on retrospective studies of routinely collected data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"542"}}